Initiatives to support export development of drugs incorporated in the draft of the strategy “Pharma-2030”, find their reflection in plans for development of the... Exports may become the main growth driver for the Russian pharmaceutical manufacturers in the coming years

Initiatives to support export development of drugs incorporated in the draft of the strategy “Pharma-2030”, find their reflection in plans for development of the Russian pharmaceutical manufacturers.

“We see exports as a good opportunity for business development and our production sites” – said in an interview with “FV” the President of the company “Akrikhin” Denis Chetverikov. He stressed that this business includes mainly the countries of the CIS, although the company is already trying to go beyond these limits.

“For example, is now quite actively explore the Vietnamese market, and in General working on a program of export development in the CIS countries, – said the head of the company. – Plan to identify priority markets for development, the key steps that needs to be done. This is a good opportunity for business development and our production site, but of course, much will depend on the development of the regulatory component, so you need to remain in dialogue with the government.”

Earlier, in an interview with “FV” CEO “Coloform” Oleg Zherebtsov expressed the opinion that the main advantage of Russian pharmaceutical companies in negotiations with potential foreign partners — low cost products at high quality.

“We sell abroad their products in several million dollars a year, and we believe that export is the main growth driver of the pharmaceutical companies in the coming three to five years,” said Mr. Stallions.

No comments so far.

Be first to leave comment below.

Your email address will not be published. Required fields are marked *